search
Back to results

Mechanisms and Treatment of Intradialytic Hypertension (MATCH)

Primary Purpose

Intradialytic Hypertension

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Carvedilol
Sponsored by
University of Texas Southwestern Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intradialytic Hypertension focused on measuring Hypertension, Hemodialysis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • on hemodialysis > 30 days
  • aged 18 to 80 years old
  • ability to provide informed consent
  • Primary nephrologist deems patient is at target dry weight
  • Predialysis SBP >140 or postdialysis SBP>130

Exclusion Criteria:

  • Patients with active wounds
  • Blood pressure unable to be measured by routine mechanisms in the upper extremity
  • Change in blood pressure medications in the previous 2 weeks
  • Intolerance of beta or alpha-blockers
  • pregnancy
  • Resting heart rate <50
  • Life expectancy < 6 months
  • Current therapy with carvedilol or contraindication to carvedilol (ONLY in the intervention arm)

Sites / Locations

  • UTSW Oakcliff Davita Dialysis
  • UTSW Dallas East Davita Dialysis (Buckner unit)
  • UTS Dallas Dialysis (Elmbrook)

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Control

Intervention

Arm Description

Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions

Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions

Outcomes

Primary Outcome Measures

Endothelial Progenitor Cells
ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry

Secondary Outcome Measures

Flow Mediated Vasodilation
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later

Full Information

First Posted
January 21, 2009
Last Updated
October 12, 2020
Sponsor
University of Texas Southwestern Medical Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00827775
Brief Title
Mechanisms and Treatment of Intradialytic Hypertension
Acronym
MATCH
Official Title
Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine in a cross sectional case-controlled cohort study of 50 hemodialysis patients if blood pressure elevations with hemodialysis are associated with decreased endothelial cell function (measured by brachial artery flow mediated dilation and endothelial progenitor cell number), both of which are novel mechanistic markers in the causal pathway for detrimental cardiovascular outcomes; and To determine if lowering blood pressure with carvedilol in 25 ESRD subjects with blood pressure elevations with hemodialysis can improve endothelial cell dysfunction as a surrogate mechanistic marker for improving cardiovascular outcomes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intradialytic Hypertension
Keywords
Hypertension, Hemodialysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
55 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
Intervention Type
Drug
Intervention Name(s)
Carvedilol
Intervention Description
Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
Primary Outcome Measure Information:
Title
Endothelial Progenitor Cells
Description
ALDH bright cells reported as percentage of mononuclear cells. These were assayed using flow cytometry CD34/CD133 endothelial progenitor cells reported as percentage of mononuclear cells. These were assayed using flow cytometry
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Flow Mediated Vasodilation
Description
Measured as percent change in brachial artery diameter from baseline to post shear stress for an individual measurement. Follow up measurements were obtained in intervention subjects 12 weeks later
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: on hemodialysis > 30 days aged 18 to 80 years old ability to provide informed consent Primary nephrologist deems patient is at target dry weight Predialysis SBP >140 or postdialysis SBP>130 Exclusion Criteria: Patients with active wounds Blood pressure unable to be measured by routine mechanisms in the upper extremity Change in blood pressure medications in the previous 2 weeks Intolerance of beta or alpha-blockers pregnancy Resting heart rate <50 Life expectancy < 6 months Current therapy with carvedilol or contraindication to carvedilol (ONLY in the intervention arm)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jula K Inrig, MD, MHS
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UTSW Oakcliff Davita Dialysis
City
Dallas
State/Province
Texas
ZIP/Postal Code
75224
Country
United States
Facility Name
UTSW Dallas East Davita Dialysis (Buckner unit)
City
Dallas
State/Province
Texas
ZIP/Postal Code
75228
Country
United States
Facility Name
UTS Dallas Dialysis (Elmbrook)
City
Dallas
State/Province
Texas
ZIP/Postal Code
75247
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22700888
Citation
Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. Clin J Am Soc Nephrol. 2012 Aug;7(8):1300-9. doi: 10.2215/CJN.10010911. Epub 2012 Jun 14.
Results Reference
result
PubMed Identifier
21757643
Citation
Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto RD. Intradialytic hypertension and its association with endothelial cell dysfunction. Clin J Am Soc Nephrol. 2011 Aug;6(8):2016-24. doi: 10.2215/CJN.11351210. Epub 2011 Jul 14.
Results Reference
result
PubMed Identifier
21734087
Citation
Van Buren PN, Kim C, Toto R, Inrig JK. Intradialytic hypertension and the association with interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2011 Jul;6(7):1684-91. doi: 10.2215/CJN.11041210.
Results Reference
result

Learn more about this trial

Mechanisms and Treatment of Intradialytic Hypertension

We'll reach out to this number within 24 hrs